192 related articles for article (PubMed ID: 38256385)
21. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
[TBL] [Abstract][Full Text] [Related]
22. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.
Haywood C; Beach MC; Bediako S; Carroll CP; Lattimer L; Jarrett D; Lanzkron S
Am J Hematol; 2011 Jan; 86(1):85-7. PubMed ID: 21117058
[TBL] [Abstract][Full Text] [Related]
23. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
25. Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators.
Pizzo A; Porter JS; Carroll Y; Burcheri A; Smeltzer MP; Beestrum M; Nwosu C; Badawy SM; Hankins JS; Klesges LM; Alberts NM
Br J Haematol; 2023 Dec; 203(5):712-721. PubMed ID: 37691131
[TBL] [Abstract][Full Text] [Related]
26. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
Green NS; Manwani D; Matos S; Hicks A; Soto L; Castillo Y; Ireland K; Stennett Y; Findley S; Jia H; Smaldone A
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643377
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
[TBL] [Abstract][Full Text] [Related]
28. Outcome of Hydroxyurea Use in SCD and Evaluation of Patients' Perception and Experience in Nigeria.
Chianumba RI; Ofakunrin AOD; Morrice J; Olanrewaju O; Oniyangi O; Kuliya-Gwarzo A; Nnebe-Agumadu U; Isa HA; Nnodu OE
Front Genet; 2022; 13():826132. PubMed ID: 35401653
[No Abstract] [Full Text] [Related]
29. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
31. Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia.
Gohal GA; Gosadi IM; Cittana Iqbal BA; Ghazwani YH; Daghriri AM; Shugairi AA; Daghriri KA; Zurayyir AJ; Nemri AA; Abdulhaq MA
Patient Prefer Adherence; 2022; 16():3059-3067. PubMed ID: 36387052
[TBL] [Abstract][Full Text] [Related]
32. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
[TBL] [Abstract][Full Text] [Related]
33. Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.
Treadwell MJ; Du L; Bhasin N; Marsh AM; Wun T; Bender MA; Wong TE; Crook N; Chung JH; Norman S; Camilo N; Cavazos J; Nugent D
Front Genet; 2022; 13():921432. PubMed ID: 36092883
[TBL] [Abstract][Full Text] [Related]
34. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.
Jabour SM; Beachy S; Coburn S; Lanzkron S; Eakin MN
J Racial Ethn Health Disparities; 2019 Dec; 6(6):1233-1243. PubMed ID: 31410784
[TBL] [Abstract][Full Text] [Related]
35. The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
Alkhalifah SA; Alanazi M; Almasaoud MA; Al-Malki HS; Al-Murdhi FM; Al-Hazzaa MS; Al-Mufarrij SM; Albabtain MA; Alshiakh AA; AlRuthia Y
BMC Emerg Med; 2022 Nov; 22(1):188. PubMed ID: 36447134
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
37. Do difficulties in swallowing medication impede the use of hydroxyurea in children?
Bekele E; Thornburg CD; Brandow AM; Sharma M; Smaldone AM; Jin Z; Green NS
Pediatr Blood Cancer; 2014 Sep; 61(9):1536-9. PubMed ID: 24753149
[TBL] [Abstract][Full Text] [Related]
38. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.
Hodges JR; Phillips SM; Norell S; Nwosu C; Khan H; Luo L; Badawy SM; King A; Tanabe P; Treadwell M; Rojas Smith L; Calhoun C; Hankins JS; Porter J
Blood Adv; 2020 Sep; 4(18):4463-4473. PubMed ID: 32941646
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman.
Jose J; Elsadek RA; Jimmy B; George P
Oman Med J; 2019 Jul; 34(4):327-335. PubMed ID: 31360322
[TBL] [Abstract][Full Text] [Related]
40. A systematic review on hydroxyurea therapy for sickle cell disease in India.
Pandey A; Kaur H; Borah S; Khargekar N; Karra VK; Adhikari T; Jain D; Madkaikar M
Indian J Med Res; 2022 Aug; 156(2):299-311. PubMed ID: 36629190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
